![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 43, 40018-40024, October 26, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, May 22, 2001, and in revised form, August 15, 2001
Previous studies have demonstrated that the
potency and thermodynamic stability of human insulin are enhanced in
concert by substitution of ThrA8 by arginine or
histidine. These surface substitutions stabilize the N-terminal
The functional surface of insulin has long been the object of
speculation (1-3). Despite many years of investigation by mutagenesis, NMR spectroscopy and x-ray crystallography, structures of insulin and
insulin analogs do not consistently predict relative potencies (3-8).
These observations suggest that a change in structure occurs on
receptor binding (7, 8). This intriguing but controversial hypothesis
(9) has motivated examination of the relationship between the
thermodynamic stability of insulin analogs and receptor binding
(10). Do mutations that stabilize the native insulin T state
(Fig. 1) also enhance receptor binding,
and if so, how can such effects be compatible with an induced fit
mechanism of hormone-receptor recognition? The present study
demonstrates that, contrary to a previous proposal (10), the activity
and stability of insulin are uncorrelated among a set of A chain
analogs. The substitutions affect the C-terminal residue and putative
electrostatic capping box of a conserved recognition A subset of insulin analogs with enhanced potency has been found to
exhibit enhanced stability (Table I and
Ref. 10). This influential study focused on the substitution of
ThrA8 in human insulin by alanine, histidine, or arginine.
The A8 site defines one edge of the classical receptor-binding surface
of insulin (1-3) and delimits the A1-A8
Activities of Monomeric Insulin Analogs at Position A8 Are
Uncorrelated with Their Thermodynamic Stabilities*
§,
,
,
,
, and
§
Department of Biochemistry, Case
Western Reserve University, Cleveland, Ohio 44106-4935, the
¶ Department of Biochemistry and Molecular Biology, University of
Chicago, Chicago, Illinois, and the
Department of Biochemistry
and Molecular Biology, Mount Sinai School of Medicine of New York
University, New York, New York 10029
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helix of the A chain, a key element of hormone-receptor recognition. Does enhanced stability necessarily imply enhanced activity? Here, we test by structure-based mutagenesis the relationship between the stability and activity of the hormone. To circumvent confounding effects of insulin self-association, A chain analogs were
combined with a variant B chain (AspB10,
LysB28, and ProB29 (DKP)) to create a monomeric
template. Five analogs were obtained by chain combination; disulfide
pairing proceeded in each case with native yield. CD and
1H NMR spectra of the DKP analogs are essentially identical
to those of DKP-insulin, indicating a correspondence of structures. Receptor binding affinities were determined by competitive displacement of 125I-insulin from human placental membranes.
Thermodynamic stabilities were measured by CD titration; unfolding was
monitored as a function of guanidine concentration. In this broader
collection of analogs receptor binding affinities are uncorrelated with
stability. We suggest that receptor binding affinities of A8 analogs
reflect local features of the hormone-receptor interface rather than
the stability of the free hormone or the intrinsic C-capping propensity of the A8 side chain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helix.

View larger version (23K):
[in a new window]
Fig. 1.
Stereo ribbon representation of the porcine
insulin monomer, as inferred from the crystal structure of 2-Zn
(T6) porcine insulin (molecule 1; Chinese nomenclature)
(3). The B chain is shown in black, and the A chain is
shown in gray. The asterisk in the left-hand
panel indicates the A8 side chain (threonine). For reference the four
tyrosine and two phenylalanine side chains are also shown; these
provide informative NMR probes as shown in Fig. 4. The NMR structure of
DKP insulin (16) resembles the crystallographic T state protomer
(3).
-helix
(asterisk in Fig. 1). The enhanced activities of the
HisA8 and ArgA8 analogs (relative to
ThrA8) were ascribed to thermodynamic stabilization of this
critical helix because of their higher helical propensities, including more favorable C-cap properties (11, 12). Additional stability may
derive from an electrostatic interaction between the A8 side chain and
the negative charge of GluA4 (a potential C-capping box;
Ref. 10). Whether a correlation between stability and activity is
general or limited to these particular analogs is not known. Because
this issue has functional implications in relation to the active
conformation of insulin, we prepared multiple analogs, including
substitutions containing negative and polar side chains at A8. In this
broader collection we find that activity and stability are
uncorrelated. A negatively charged GluA8 substitution, for
example, stabilizes the free hormone but impairs receptor binding. The
contribution of a putative [GluA4, HisA8]
electrostatic capping box to the stability and activity of insulin was
tested by the second site substitution GluA4
Ala and
found not to be significant.
Past studies of A8 analogs of human insulin

Experimental design employs an engineered insulin monomer as a
framework for A8 substitutions. The monomer, designated DKP-insulin (13-15), exhibits enhanced activity. Self association is prevented by
three substitutions in the B chain (AspB10,
LysB28, and ProB29) as described previously
(13). The solution structure of DKP-insulin (16) resembles the
crystallographic T state (Ref. 3 and Fig. 1). The DKP B chain is
readily combined with variant A chains to provide a monomeric template
(15). In this article we describe the synthesis and characterization of
five analogs of DKP-insulin. Our results demonstrate that receptor
binding is uncorrelated with either observed thermodynamic stabilities
or tabulated helical capping propensities (11, 12). We propose a model
in which the A8 side chain lies at the periphery of the insulin
receptor and can thus introduce favorable or unfavorable local
interactions at the edge of the receptor. Diverse side chains
are readily accommodated at this edge and may be incorporated
into novel analogs of therapeutic interest.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials
4-Methylbenzhydrylamine resin (0.6 mmol of amine/g; Star Biochemicals, Inc.) was used as solid support for synthesis of A chain analogs; (N-tert-butoxycarbonyl, O-benzyl)-threonine-phenylacetamidomethyl resin (0.56 mmol/g; Bachem, Inc.) was used as solid support for synthesis of the DKP B chain analog. N-tert-Butoxycarbonyl-amino acids and derivatives were obtained from Bachem and Peninsula Laboratories; N,N'-dicyclohexylcarbodiimide and N-hydroxybenzotriazole (recrystallized from 95% ethanol) were from Fluka. Amino acid analyses of synthetic chains and insulin analogs were performed after acid hydrolysis; protein determinations were carried out by the Lowry method using native insulin as standard. Chromatography resins were preswollen microgranular carboxymethylcellulose (CM-cellulose; Whatman CM52), DE53 cellulose (Whatman), and Cellex E (Ecteola cellulose; Sigma); solvents were HPLC1 grade.
Peptide Synthesis
The general protocol for solid phase synthesis is as described
(17). A manual double-coupling protocol was followed (18, 19). The
C-terminal Asn in the synthesis of the A chain was incorporated into
solid support by coupling N-tert-butoxycarbonyl Asp-
-benzyl ester with 4-methylbenzhydrylamine resin. After the final deprotection the Asp residue was converted to an Asn residue.
Synthetic A chain S-Sulfonate Analogs-- From 606 mg of GluA8 peptidyl resin, after deblocking, sulfitolysis, and chromatographic purification, ~116 mg of purified S-sulfonated A chain were obtained. After analogous processing the following yields of other analogs were obtained: 125 mg of purified S-sulfonated chain from ~602 mg of GlnA8 peptidyl resin, ~235 mg of purified chain from 1.03 g of HisA8 peptidyl resin, ~165 mg of purified chain from 0.8 g of [AlaA4, HisA8] peptidyl resin, and 136 mg of purified chain from 0.75 g of AlaA4 peptidyl resin. AlaA2 A chain was also prepared as a negative control (see text).
Synthetic B Chain S-Sulfonate-- From 610 mg of [AspB10, LysB28, ProB29] peptidyl resin after deblocking, sulfitolysis and chromatographic purification, ~125 mg of purified S-sulfonated B chain was obtained.
Peptide Purification
Crude S-sulfonated A chains were purified by chromatography on a Cellex E column (1.5 × 47 cm) as described (18, 19), dialyzed against distilled water, and lyophilized to yield the purified A chain S-sulfonate A8 analogs. Crude S-sulfonated DKP B chain was likewise purified on a cellulose DE53 column (1.5 × 47 cm), dialyzed, and lyophilized to yield the [AspB10, LysB28, ProB29] B chain S-sulfonate.
Chain Recombination
Chain recombination employed S-sulfonated A chain and DKP B chain (~2:1 by weight) in 0.1 M glycine buffer (pH 10.6) in presence of dithiothreitol. Insulin analogs were isolated from the combination mixture as described (18, 19) and purified on a CM-cellulose column (0.9 × 23 cm) and reverse-phase HPLC on a Vydac 218 TP column (0.46 × 25 cm); the latter used a flow rate of 0.5 ml/min with 20-80% linear gradient of 80% aqueous acetonitrile containing 0.1% trifluoroacetic acid over 80 min. Rechromatography of this material on reverse-phase HPLC under the same conditions gave in each case a single sharp peak. The HisA8 A chain was also combined with the native human B chain to obtain HisA8 human insulin as a positive control. Amino acid analyses and mass spectrometry in each case gave expected values.
Receptor Binding Studies
Radiolabeled [125I-TyrA14]human
insulin was purchased from Amersham Pharmacia Biotech. Receptor binding
assays of insulin analogs were performed as described (20) with minor
modifications. Human placental cell membranes were prepared (21),
stored at
80 °C in small aliquots, and thawed prior to use.
Membrane fragments (0.025 mg protein/tube) were incubated with
radiolabeled insulin (~30,000 cpm) in the presence of selected
concentrations of unlabeled peptide for 18 h at 4 °C in a final
volume of 0.25 ml of 0.05 M Tris-HCl and 0.25% (w/v)
bovine serum albumin at pH 8. Subsequent to incubation, each mixture
was diluted with 1 ml of ice-cold buffer and centrifuged (10,000 × g) for 5 min at 4 °C. The supernatant was then removed
by aspiration, and the membrane pellet was counted for radioactivity.
The data were corrected for nonspecific binding (amount of
radioactivity remaining membrane-associated in the presence of 1 µM human insulin). Each determination was performed with
three or four replicates (Table II); the
values are reported as the mean and standard deviation of these
multiple measurements. Binding studies of control analog
HisA8 human insulin were undertaken with both
placenta-derived membrane fragments at 4 °C and hepatic insulin
receptor preparations at 24 °C (17, 18).
|
Spectroscopy
1H NMR spectra of DKP-insulin and DKP analogs were
obtained at 500 or 600 MHz at 25 °C in aqueous solution (pH 7.0; pD
6.6, direct meter reading); the protein concentration was 1.5 mM. Resonance assignment for DKP-insulin has been described
(16) and extended by inspection to analogs. CD spectra of DKP-insulin
analogs were obtained using an Aviv spectropolarimeter equipped with
thermister temperature control and automated titration unit for
guanidine denaturation studies. Denaturation studies were conducted in
10 mM potassium phosphate (pH 7.4) and 50 mM
KCl. CD spectra were obtained at a protein concentration of 50 µM; the samples were diluted to 5 µM for
equilibrium denaturation studies (Fig. 3, C and F). To allow comparison with the
conditions used by Kaarsholm and co-workers (10), guanidine
denaturation CD studies were repeated for human insulin and
HisA8 DKP-insulin in 10 mM Tris-perchloric acid
(pH 8.0) at 25 °C. The data were fitted by nonlinear least squares
to a two-state model as described (22). Native and variant proteins
exhibit similar m values; the conclusions are not affected
by recalibration of the m value (slope) used in the linear
extrapolation formalism.
|
Control Studies
The values obtained herein for activity and stability in part differ from published reports because of conditions of study.
Receptor Binding Studies-- Use of placental membrane preparations at 4 °C leads to lower estimates of enhanced activity than use of hepatic membrane preparations at 24 °C (18) or IM-9 lymphocyte membranes at 15 °C (23). Positive control studies of HisA8 human insulin yielded values of 212% ± 34 in the placental membrane assay and higher values in our hands (450-550%) in the hepatic membrane assay in accord with published values (10). Negative control studies of a low affinity substitution (AlaA2 DKP-insulin) in the placental membrane assay yielded values of ~1%, which is also in accord with published values (24, 25).
Guanidine Titrations--
The HisA8 substitution in
the context of DKP-insulin enhances stability at 4 °C by 0.4 ± 0.1 kcal/mol, which is less than its reported stabilizing effect in the
context of native insulin at 25 °C (
Gu
1.7 kcal/mol; Table I and Ref. 10). To test whether this reflects a
difference in experimental conditions or template context (DKP-insulin
versus native insulin), we reinvestigated the stability of
human insulin and HisA8 insulin relative to human insulin
at 4 and 25 °C. The stabilizing effect of HisA8 at
4 °C (
Gu 0.5 ± 0.2 kcal/mol) is similar to
that in the DKP context. The higher values reported at 25 °C (10)
are reproducible in our hands and reflect the lower relative stability
of native human insulin at higher temperatures.
| |
RESULTS |
|---|
|
|
|---|
Five analogs of DKP-insulin were prepared by total synthesis (Table II and "Experimental Procedures"). Chain combination yielded native disulfide pairing with efficiencies similar to that observed in the total synthesis of native insulin. Non-native disulfide isomers (26) were not observed. Use of the monomeric DKP template simplifies biophysical analysis by avoiding possible confounding effects of insulin self-association (15).
Analogs Exhibit Native Overall Structure--
CD spectra of the
analogs exhibit similar helix contents relative to DKP-insulin as
illustrated in Fig. 3 (A and
D). 1H NMR spectra (pH 7 and 25 °C) are
similar to those of DKP-insulin; each analog exhibits comparable
nonrandom dispersion of chemical shifts characteristic of the T state
structure. In addition, each spectrum retains the pattern of resonance
line widths and chemical shifts diagnostic of the monomeric state (14).
Two-dimensional total correlation 1H NMR spectra reveal
essentially identical spin systems with corresponding chemical shifts.
This correspondence is illustrated for three analogs (Fig.
4); the aromatic resonance of the
proteins four tyrosines and three phenylalanines provide intrinsic
probes of the major structural elements of the hormone. An example is
provided by the chemical shifts of PheB24 and
TyrA19, whose large secondary shifts reflect their distinct
environments in the native hydrophobic core (Fig. 1). Such
correspondence of chemical shifts provides evidence of structural
similarity.
|
|
Receptor Binding Affinities and Thermodynamic Stability Are
Uncorrelated--
GluA8 and GlnA8 analogs
differ by a single functional group: a side chain carboxylate or
carboxamide. The results of activity and stability measurements are
given in Table II. Whereas the activity of GlnA8
DKP-insulin is ~120% (relative to human insulin), the
GluA8 analog is 2-fold less active. Analysis of protein
unfolding by contrast demonstrates opposing differences in
thermodynamic stability (Fig. 3F). Whereas
DKP-insulin exhibits a cooperative and apparent two-state transition
with
Gu 4.8 ± 0.1 kcal/mol, GluA8
DKP-insulin and HisA8 DKP-insulin each exhibit enhanced
stability (
Gu = 5.9 ± 0.1 and 5.2 ± 0.1 kcal/mol, respectively; see Table II). Surprisingly, the extent
of stabilization conferred by GluA8
(
Gu = 1.1 ± 0.2 kcal/mol) is greater
than that conferred by HisA8 (
Gu = 0.4 ± 0.2 kcal/mol). Substitution of the negative
GluA8 charge by a neutral GlnA8 carboxamide
attenuates the enhancement in stability. Although qualitative
inspection of the unfolding curves strongly suggests that
GlnA8 DKP-insulin is slightly more stable than DKP-insulin
in accord with its greater Cmid guanidine
concentration (Table II), the inferred increment in stability is
imprecisely determined (
Gu = 0.2 ± 0.3 kcal/mol).
Comparison of GluA8 and GlnA8 analogs thus
demonstrates that a negative charge at A8 can be as stabilizing as was
reported for a positive charge (ArgA8; Table I) but less
active than a neutral isostere (GlnA8). The native DKP
monomer and A8 analogs exhibit similar
temperature-dependent changes in mean residue ellipticity
at 222 nm in the range 4-50 °C (Fig. 3, B and
E). To test whether the enhanced stability of HisA8 DKP-insulin is due to an electrostatic capping box
involving GluA4, the latter side chain was substituted by
alanine to yield the two analogs AlaA4 DKP-insulin and
[AlaA4, HisA8] insulin. In either context the
alanine substitution is destabilizing by 0.2 kcal/mol. Although this
destabilizing effect is consistent with a general contribution of
GluA4 to stability, our results exclude a specific role for
a putative [GluA4, HisA8] capping box:
introduction of a negative charge at A4 is no more stabilizing relative
to [AlaA4, HisA8] than it is relative to
[AlaA4, ThrA8]. The destabilizing
GluA4
Ala substitution does not impair receptor binding
activity in either context.
| |
DISCUSSION |
|---|
|
|
|---|
The present study addresses two questions: can the stability of
insulin be engineered through the use of general principles of peptide
chemistry (27, 28), and if so, can such engineering be exploited to
enhance its activity? These questions were posed by an influential
study by Kaarsholm et al. (10) in which rational optimization of the C-terminal capping box of the A1-A8
-helix (11,
12) was found to enhance stability and activity in concert (Table I).
The present experimental design has tested whether such enhancement is
related to the biophysical rationale of the design or is coincidental.
Two sets of analogs were synthesized and characterized. First,
GluA8 and GlnA8 DKP-insulin enable comparison
of two isosteric side chains differing by a single function: the
negatively charged carboxylate versus the polar carboxamide.
We have found that GluA8 enhances the stability of insulin,
which would not be expected based on an electrostatic C-capping
mechanism in an isolated
-helix (11, 12). A negative charge at A8
would in fact seem to be unfavorable because of repulsion by the
helical dipole and neighboring presence of GluA4. It is
possible that the stabilization of the analog is due to the greater
helical propensity of Glu (relative to Thr) irrespective of segmental
electrostatic interactions. Despite such enhanced stability, the
GluA8 analog is ~3-fold less active than its parent
DKP-insulin in receptor binding. The stability of GlnA8
DKP-insulin is similar to that of DKP-insulin. Because Gln and Glu have
similar helical propensities (11, 12) and GlnA8 would not
incur unfavorable local electrostatic interactions, it is not clear why
GluA8 DKP-insulin is substantially more stable than
GlnA8 DKP-insulin. Electrostatic contributions to protein
stability are complex, including long range interactions, changes in
solvation, and distribution of counter ions. The activity of
GlnA8 DKP-insulin is between that of GluA8
DKP-insulin and DKP-insulin (Table II).
We next examined the stabilizing mutation HisA8. Our
results confirm that this substitution enhances the stability of
insulin, although the extent of enhancement is smaller at 4 °C than
at 25 °C because of differential thermal destabilization of insulin. GluA4
Ala substitutions were introduced into
DKP-insulin and HisA8 DKP-insulin to test whether such
enhanced stability is due to an (i, i + 4)
electrostatic capping interaction. The AlaA4 substitution
causes the same small decrement in stability in either context. These
results suggest that an (i, i + 4) interaction, if present, does not contribute to stability. Thus, whereas physical mechanisms stabilizing insulin must include contributions from foundational principles of helical stabilization (24, 25), these
factors are not predominant at the A8 position. The GluA4
Ala substitution has previously been shown to enhance slightly the
activity of native insulin (10, 29). Our results are consistent with
this but not sufficiently precise to provide a rigorous assessment. We
can conclude, however, that elimination of a putative interaction between the side chains of GluA4 and HisA8 in
[AlaA4, HisA8] DKP-insulin does not impair
receptor binding activity.
Optimization of stability by protein engineering does not in general
provide a consistent criterion for enhancing receptor binding.
Mutations that enhance the stability of a DNA-binding domain, for
example, do not consistently enhance DNA affinity at permissive
temperatures (30). The stability of a protein (
Gu) reflects an overall equilibrium between
folded and unfolded states of a protein. A mutational increase in
Gu from 4 to 5.4 kcal/mol, for example, would
correspond to an increase in the fraction of folded insulin molecules
in an ensemble from 0.9990 to 0.9999%. Should the folded state be the
active conformation, such a change would in itself predict only a
marginal increase in the availability of active molecules; the
associated enhancement in receptor binding would be negligible. Should
the folded state be inactive, then stabilizing mutations might even
impair activity. In either case the present results, excluding a
general correlation between the stability and activity of insulin, are
not inconsistent with thermodynamic principles.
Activity of A8 analogs could be enhanced or impaired by three possible residue-specific mechanisms: (i) the mutation could cause a local or nonlocal structural changes in the free hormone; (ii) the mutation could facilitate or hinder a change in the hormone's conformation on receptor binding; or (iii) the mutation could stabilize or destabilize the hormone-receptor interface irrespective of its effects in the free hormone. We discuss each of these possibilities in turn.
Structural Changes in the Free Hormone--
The A8 side chain is
exposed on the surface of insulin (Fig. 1 and Refs. 1-3). Although
crystal structures of A8 analogs have not been described to date, the
NMR structure of an engineered insulin monomer containing
HisA8 has been reported (31). The structure resembles the
crystallographic T state with no non-native interactions involving the
mutant side chain. Similarly, qualitative two-dimensional NMR studies
of the present analogs demonstrate retention of a native insulin fold (Fig. 4). These data do not exclude small changes in the local structure or dynamics of the A1-A8
-helix. Because local changes may be uncorrelated with global stabilities, it remains possible that
A8 substitutions can affect activity through transmitted effects on
classical receptor-binding sites (1-3), e.g. at
GlyA1, IleA2, and ValA3. We
consider this unlikely in light of the small thermodynamic cost of
induced fit observed in receptor-binding studies of unstable two-disulfide analogs of insulin (22) and insulin-like growth factor-1
(32); segmental unfolding of the A1-A8
-helix (an extreme case of
structural and dynamic perturbation) is associated with only modest
decrements in affinity. We therefore imagine that any subtle changes in
the structure or dynamics of the A1-A8
-helix in an A8 analog could
readily be "repaired" on receptor binding.
Hindrance or Facilitation of a Conformational
Change--
Considerable speculation has focused on conformational
changes involving the C-terminal
-strand of the B chain on
receptor binding (4, 7, 8, 33-35). Detachment or destabilization of
the C-terminal
-strand is suggested, for example, by the enhanced activity of D-amino-acid substitutions at position B24
(3-5). Such a change in conformation would be expected to facilitate contacts between the receptor and the conserved side chains of IleA2 and ValA3 as illustrated in Fig.
5. Can an analogous model apply to the A
chain? Although this possibility is consistent with the modularity of
the structure of insulin (i.e. like that of the C-terminal B
chain
-strand, local folding or unfolding of the A1-A8 segment can
occur independently of the remainder of the native state; Ref. 16),
such a model is unlikely. Unlike the C-terminal B chain
-strand, the
N-terminal
-helix of the A chain appears to function as a preformed
recognition element (Fig. 5 and Refs. 22 and 31). Further, although we
cannot exclude a mechanism by which enhanced segmental stability of the
A1-A8
-helix hinders detachment of the B24-B28
-strand, the
divergent properties of GluA8 DKP-insulin (more stable but
less active) suggests that such transmitted effects are not
predominant.
|
Local Efects within the Hormone-Receptor Interface-- We propose that the variable activities of A8 insulin analogs reflect primarily the complex chemistry of the hormone-receptor interface. Differences in activity between A8 analogs would then arise from variable local interactions within the complex and not within the free hormone. In accord with classical models of the receptor-binding surface of the hormone (1-3), we imagine that ThrA8 is positioned at the edge of the receptor and that this location has a small negative electrostatic potential. Side chains containing a positive charge are slightly favored, whereas side chains containing a negative charge are slightly disfavored. Because of the variety of side chain shapes, sizes, and functionalities that can be accommodated by the receptor at the A8 site, we expect that high affinity complexes can be generated using photoreactive side chains such as para-azido-PheA8 (36) or para-benzoyl-PheA8 (37). It would be of future interest to test whether such derivatized insulins would photo-cross-link to the insulin receptor and, if so, to map sites of attachment.
In summary, the critical importance of the N-terminal
-helix of the
A chain (1-3) has focused attention on the structural basis of its
stabilization by A8 substitutions and their functional implications.
Our results verify that substitutions at A8 can modulate the stability
and activity of insulin but exclude a simple electrostatic model of how
the A8 side chain contributes to the stability of insulin and do not
substantiate a proposed relationship between stability and activity
(10). How such diverse substitutions as HisA8 and
GluA8 (but not GlnA8) enhance the stability of
insulin remains enigmatic. The complexity of protein structures and
interactions implies that changes in physical or functional properties
often reflect small differences between large entropic and enthalpic
driving forces, including those associated with solvation and counter
ion distribution. Deciphering how A8 substitutions influence the
activity of insulin will require a crystal structure of the
hormone-receptor complex (38). Such a structure would be of both basic
and applied interest in relation to diabetes therapy. Positions at the
edge of the classical receptor-binding surface of the hormone (1-3),
such as A8, B9, B10, B28, and B29, are of particular interest as sites of modification in pharmacologic design of novel analogs (39, 40).
| |
ACKNOWLEDGEMENTS |
|---|
We thank M. R. DeFelippis, B. Frank, and R. Chance (Eli Lilly and Co.) for biosynthetic human insulin and advice and P. De Meyts, G. G. Dodson, D. F. Steiner, and the late H. S. Tager for helpful discussion and communication of results prior to publication.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants from the National Institutes of Health (to M. A. W. and P. G. K.) and by the Diabetes Research & Training Center at the University of Chicago (to M. A. W. and S. H. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence may be addressed. E-mail: weiss@ biochemistry.cwru.edu (M. A. W.) or p_katsoyannis@smtplink.mssm.edu (P. G. K.).
Published, JBC Papers in Press, August 21, 2001, DOI 10.1074/jbc.M104634200
| |
ABBREVIATIONS |
|---|
The abbreviation used is: HPLC, high performance liquid chromatography.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Pullen, R. A., Lindsay, D. G., Wood, S. P., Tickle, I. J., Blundell, T. L., Wollmer, A., Krail, G., Brandenburg, D., Zahn, H., Gliemann, J., and Gammeltoft, S. (1976) Nature 259, 369-373[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Liang, D.-C., Stuart, D., Dai, J.-B., Todd, R., You, J.-M., and Lou, M.-Z. (1985) Sci. Sin. 28, 472-484 |
| 3. | Baker, E. N., Blundell, T. L., Cutfield, J. F., Cutfield, S. M., Dodson, E. J., Dodson, G. G., Hodgkin, D. M. C., Hubbard, R. E., Isaacs, N. W., Reynolds, C. D., Sakabe, K., Sakabe, N., and Vijayan, N. M. (1988) Philos. Trans. R. Soc. Lond. B. Biol. Sci. 319, 369-456[Medline] [Order article via Infotrieve] |
| 4. | Kobayashi, M., Ohgaku, S., Iwasaki, M., Maegawa, H., Shigeta, Y., and Inouye, K. (1982) Biochem. Biophys. Res. Commun. 107, 329-336[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Mirmira, R. G.,
and Tager, H. S.
(1989)
J. Biol. Chem.
264,
6349-6354 |
| 6. | Derewenda, U., Derewenda, Z., Dodson, E. J., Dodson, G. G., Reynolds, C. D., Smith, G. D., Sparks, C., and Swenson, D. (1989) Nature 338, 594-596[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Derewenda, U., Derewenda, Z., Dodson, E. J., Dodson, G. G., Bing, X., and Markussen, J. (1991) J. Mol. Biol. 220, 425-433[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Hua, Q. X., Shoelson, S. E., Kochoyan, M., and Weiss, M. A. (1991) Nature 354, 238-241[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Ludvigsen, S., Olsen, H. B., and Kaarsholm, N. C. (1998) J. Mol. Biol. 279, 1-7[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Kaarsholm, N. C., Norris, K., Jorgensen, R. J., Mikkelsen, J., Ludvigsen, S., Olsen, O. H., Sorensen, A. R., and Havelund, S. (1993) Biochemistry 32, 10773-10778[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Doig, A. J., and Baldwin, R. L. (1995) Protein Sci. 4, 1325-1336[Abstract] |
| 12. |
Chakrabartty, A.,
Doig, A. J.,
and Baldwin, R. L.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11332-11336 |
| 13. |
Brems, D. N.,
Alter, L. A.,
Beckage, M. J.,
Chance, R. E.,
DiMarchi, R. D.,
Green, L. K.,
Long, H. B.,
Pekar, A. H.,
Shields, J. E.,
and Frank, B. H.
(1992)
Protein Eng.
5,
527-533 |
| 14. | Weiss, M. A., Hua, Q. X., Lynch, C. S., Frank, B. H., and Shoelson, S. E. (1991) Biochemistry 30, 7373-7389[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Shoelson, S. E, Lu, Z., X, Parlautan, L., Lynch, C., S., and Weiss, M., A,. (1992) Biochemistry 31, 1757-1767[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Hua, Q. X., Hu, S. Q., Frank, B. H., Jia, W., Chu, Y. C., Wang, S. H., Burke, G. T., Katsoyannis, P. G., and Weiss, M. A. (1996) J. Mol. Biol. 264, 390-403[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Merrifield, R. B., Vizioli, L. D., and Boman, H. G. (1982) Biochemistry 21, 5020-5031[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Chu, Y. C., Hu, S. Q., Zong, L., Burke, G. T., Gammeltoft, S., Chan, S. J., Steiner, D. F., and Katsoyannis, P. G. (1994) Biochemistry 33, 11278-11285[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Hu, S. Q., Burke, G. T., Schwartz, G. P., Ferderigos, N., Ross, J. B., and Katsoyannis, P. G. (1993) Biochemistry 32, 2631-2635[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Cara, J. F.,
Mirmira, R. G.,
Nakagawa, S. H.,
and Tager, H. S.
(1990)
J. Biol. Chem.
265,
17820-17825 |
| 21. | Marshall, R. N., Underwood, L. E., Voina, S. J., Foushee, D. B., and Van Wyk, J. J. (1974) J. Clin. Endocrinol. Metab. 39, 283-292[Medline] [Order article via Infotrieve] |
| 22. | Weiss, M. A., Hua, Q. X., Jia, W., Chu, Y. C., Wang, R. Y., and Katsoyannis, P. G. (2000) Biochemistry 39, 15429-15440[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | De Meyts, P. (1994) Diabetologia 37 (Suppl. 2), S135-S148 |
| 24. | Kitagawa, K., Ogawa, H., Burke, G. T., Chanley, J. D., and Katsoyannis, P. G. (1984) Biochemistry 23, 1405-1413[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Nakagawa, S. H., and Tager, H. S. (1992) Biochemistry 31, 3204-3214[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Hua, Q. X., Gozani, S. N., Chance, R. E., Hoffmann, J. A., Frank, B. H., and Weiss, M. A. (1995) Nat. Struct. Biol. 2, 129-138[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Myers, J. K., Pace, C. N., and Scholtz, J. M. (1997) Biochemistry 36, 10923-10929[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Dahiyat, B. I., Gordon, D. B., and Mayo, S. L. (1997) Protein Sci. 6, 1333-1337[Abstract] |
| 29. |
Kristensen, C.,
Kjeldsen, T.,
Wiberg, F, C,
Schaffer, L.,
Hach, M.,
Havelund, S.,
Bass, J.,
Steiner, D. F.,
and Andersen, A. S.,.
(1997)
J. Biol. Chem.
272,
12978-12983 |
| 30. | Sauer, R. T., Jordan, S. R., and Pabo, C. O. (1990) Adv. Protein. Chem. 40, 1-61[Medline] [Order article via Infotrieve] |
| 31. | Olsen, H. B., Ludvigsen, S., and Kaarsholm, N. C. (1998) J. Mol. Biol. 284, 477-488[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Narhi, L. O., Hua, Q. X., Arakawa, T., Fox, G. M., Tsai, L., Rosenfeld, R., Holst, P., Miller, J. A., and Weiss, M. A. (1993) Biochemistry. 32, 5214-5221[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Kobayashi, M., Ohgakv, S., Iwasaki, M., Maegawa, H., Shigeta, Y., and Inouye, K. (1982) Biochem. J. 206, 597-603[Medline] [Order article via Infotrieve] |
| 34. |
Nakagawa, S. H.,
and Tager, H. S.
(1987)
J. Biol. Chem.
262,
12054-12058 |
| 35. |
Mirmira, R. G.,
Nakagawa, S. H.,
and Tager, H. S.
(1991)
J. Biol. Chem.
266,
1428-1436 |
| 36. |
Kurose, T.,
Pashmforoush, M.,
Yoshimasa, Y.,
Carroll, R.,
Schwartz, G. P.,
Burke, G. T.,
Katsoyannis, P. G.,
and Steiner, D. F.
(1994)
J. Biol. Chem.
269,
29190-29197 |
| 37. |
Shoelson, S. E.,
Lee, J.,
Lynch, C. S.,
Backer, J. M.,
and Pilch, P. F.
(1993)
J. Biol. Chem.
268,
4085-4091 |
| 38. | Garrett, T. P., McKern, N. M., Lou, M., Frenkel, M. J., Bentley, J. D., Lovrecz, G. O., Elleman, T. C., Cosgrove, L. J., and Ward, C. W. (1998) Nature 394, 395-399[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Brange, J., Ribel, U., Hansen, J. F., Dodson, G., Hansen, M. T., Havelund, S., Melberg, S. G., Norris, F., Norris, K., Snel, L., Sorensen, A. R., and Voigt, H. O. (1988) Nature 333, 679-682[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Buse, J. B. (2001) Curr. Opin. Endo. Diabetes 8, 95-100 |
| 41. | Sosnick, T. R., Fang, X., and Shelton, V. M. (2000) Methods Enzymol. 317, 393-409[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
Q.-x. Hua, S. H. Nakagawa, W. Jia, K. Huang, N. B. Phillips, S.-q. Hu, and M. A. Weiss Design of an Active Ultrastable Single-chain Insulin Analog: SYNTHESIS, STRUCTURE, AND THERAPEUTIC IMPLICATIONS J. Biol. Chem., May 23, 2008; 283(21): 14703 - 14716. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Huang, S. J. Chan, Q.-x. Hua, Y.-C. Chu, R.-y. Wang, B. Klaproth, W. Jia, J. Whittaker, P. De Meyts, S. H. Nakagawa, et al. The A-chain of Insulin Contacts the Insert Domain of the Insulin Receptor: PHOTO-CROSS-LINKING AND MUTAGENESIS OF A DIABETES-RELATED CREVICE J. Biol. Chem., November 30, 2007; 282(48): 35337 - 35349. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-x. Hua, M. Liu, S.-Q. Hu, W. Jia, P. Arvan, and M. A. Weiss A Conserved Histidine in Insulin Is Required for the Foldability of Human Proinsulin: STRUCTURE AND FUNCTION OF AN ALAB5 ANALOG J. Biol. Chem., August 25, 2006; 281(34): 24889 - 24899. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-x. Hua, S. Nakagawa, S.-Q. Hu, W. Jia, S. Wang, and M. A. Weiss Toward the Active Conformation of Insulin: STEREOSPECIFIC MODULATION OF A STRUCTURAL SWITCH IN THE B CHAIN J. Biol. Chem., August 25, 2006; 281(34): 24900 - 24909. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Nakagawa, Q.-x. Hua, S.-Q. Hu, W. Jia, S. Wang, P. G. Katsoyannis, and M. A. Weiss Chiral Mutagenesis of Insulin: CONTRIBUTION OF THE B20-B23 beta-TURN TO ACTIVITY AND STABILITY J. Biol. Chem., August 4, 2006; 281(31): 22386 - 22396. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-y. Zhang, M. Liu, and P. Arvan Behavior in the Eukaryotic Secretory Pathway of Insulin-containing Fusion Proteins and Single-chain Insulins Bearing Various B-chain Mutations J. Biol. Chem., January 31, 2003; 278(6): 3687 - 3693. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Xu, Q.-X. Hua, S. H. Nakagawa, W. Jia, Y.-C. Chu, P. G. Katsoyannis, and M. A. Weiss A cavity-forming mutation in insulin induces segmental unfolding of a surrounding {alpha}-helix Protein Sci., January 1, 2002; 11(1): 104 - 116. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||